Legal & General Group PLC Akebia Therapeutics, Inc. Transaction History

Legal & General Group PLC

$431 Billion
Q3 2025

A detailed history of Legal & General Group PLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 245,251 shares of AKBA stock, worth $416,926. This represents 0.0% of its overall portfolio holdings.

Number of Shares

245,251

Previous 23,279 953.53%

Holding current value

$416,926

Previous $84,000 688.1%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$2.7 - $4.01 $599,324 - $890,107	221,972 Added 953.53%	245,251 $662,000
Q2 2025 Aug 12, 2025	BUY	$1.55 - $3.97 $7,436 - $19,048	4,798 Added 25.96%	23,279 $84,000
Q1 2025 May 15, 2025	BUY	$1.69 - $2.84 $594 - $999	352 Added 1.94%	18,481 $35,000
Q4 2024 Feb 13, 2025	SELL	$1.26 - $2.13 $715 - $1,209	-568 Reduced 3.04%	18,129 $33,000
Q3 2024 Feb 28, 2025	BUY	$0.94 - $1.55 $533 - $880	568 Added 3.13%	18,697 $24,000

Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $686 - $1,131	730 Added 4.06%	18,697 $24,000
Q2 2024 May 29, 2025	SELL	$0.86 - $1.63 $442 - $837	-514 Reduced 2.78%	17,967 $18,000
Q2 2024 Aug 14, 2024	BUY	$0.86 - $1.63 $15,451 - $29,286	17,967 New	17,967 $18,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $4,182 - $6,413	-13,943 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$0.32 - $0.67 $33,048 - $69,194	-103,276 Reduced 88.11%	13,943 $5,000
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $3,806 - $15,490	5,287 Added 4.72%	117,219 $84,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $11,044 - $16,322	4,887 Added 4.57%	111,932 $253,000
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $69,865 - $115,352	29,730 Added 38.45%	107,045 $308,000
Q2 2021 Aug 12, 2021	BUY	$2.83 - $4.2 $122,009 - $181,074	43,113 Added 126.05%	77,315 $293,000
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $75 - $131	26 Added 0.08%	34,202 $116,000
Q4 2020 Feb 12, 2021	SELL	$2.22 - $3.78 $721 - $1,228	-325 Reduced 0.94%	34,176 $96,000
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $9,593 - $52,503	-4,014 Reduced 10.42%	34,501 $87,000
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $115,764 - $235,694	17,356 Added 82.03%	38,515 $523,000
Q1 2020 May 14, 2020	SELL	$4.1 - $10.24 $20,057 - $50,094	-4,892 Reduced 18.78%	21,159 $161,000
Q3 2019 Nov 13, 2019	BUY	$3.55 - $5.4 $11,782 - $17,922	3,319 Added 14.6%	26,051 $102,000
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $24,345 - $47,800	5,938 Added 35.36%	22,732 $110,000
Q4 2018 Feb 15, 2019	BUY	$5.39 - $9.15 $50,013 - $84,902	9,279 Added 123.47%	16,794 $93,000
Q2 2018 Aug 10, 2018	SELL	$9.15 - $11.34 $6,807 - $8,436	-744 Reduced 9.01%	7,515 $75,000
Q1 2018 May 17, 2018	SELL	$9.53 - $15.68 $27,122 - $44,625	-2,846 Reduced 25.63%	8,259 $79,000
Q4 2017 Feb 13, 2018	BUY	$14.24 - $19.59 $158,135 - $217,546	11,105	11,105 $167,000

Others Institutions Holding AKBA

# of Institutions

189

Shares Held

121M

Call Options Held

267K

Put Options Held

280K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $313M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Akebia Therapeutics, Inc. Transaction History